Apollo Therapeutics Joins Forces with Sunshine Lake Pharma to Develop APL-18881 for Multiple Indications
Shots:
- Apollo has signed an exclusive licensing agreement with Sunshine to develop APL-18881 (HEC88473) for various indications, with the latter holding on to the China rights
- Apollo will get rights across ROW. Sunshine is eligible for $12M upfront, up to $926M development, regulatory & commercial milestones plus high single to low double digits net-sales-based tiered royalties
- APL-18881 (a bi-specific fusion protein targeting FGF21 and GLP-1 receptors) is in P-II trials for T2D in China, with results planned in H1’25; it has an open US IND & Apollo will develop it for undisclosed cardiometabolic, liver & related disease indications. Both of them will conduct PoC studies in 2025
Ref: Apollo Therapeutics | Image: Apollo Therapeutics
Related News:- Alteogen and Daiichi Sankyo Partner to Develop and Commercialize SC Formulation of Enhertu
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
